Y Intercept Hong Kong Ltd Purchases Shares of 14,959 GRAIL, Inc. $GRAL

Y Intercept Hong Kong Ltd bought a new position in shares of GRAIL, Inc. (NASDAQ:GRAL) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 14,959 shares of the company’s stock, valued at approximately $885,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in GRAL. Teacher Retirement System of Texas raised its holdings in shares of GRAIL by 5.5% during the second quarter. Teacher Retirement System of Texas now owns 8,538 shares of the company’s stock worth $439,000 after acquiring an additional 447 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in GRAIL by 28.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,835 shares of the company’s stock valued at $76,000 after purchasing an additional 623 shares in the last quarter. Farther Finance Advisors LLC increased its position in shares of GRAIL by 768.1% during the 2nd quarter. Farther Finance Advisors LLC now owns 816 shares of the company’s stock worth $42,000 after purchasing an additional 722 shares during the last quarter. NewEdge Advisors LLC raised its stake in shares of GRAIL by 44.0% during the 2nd quarter. NewEdge Advisors LLC now owns 2,535 shares of the company’s stock worth $130,000 after purchasing an additional 775 shares in the last quarter. Finally, Gladstone Institutional Advisory LLC lifted its stake in GRAIL by 6.4% in the third quarter. Gladstone Institutional Advisory LLC now owns 15,534 shares of the company’s stock valued at $919,000 after acquiring an additional 937 shares during the last quarter.

GRAIL Price Performance

GRAL stock opened at $97.82 on Monday. GRAIL, Inc. has a 1 year low of $20.44 and a 1 year high of $118.84. The company has a market cap of $3.81 billion, a P/E ratio of -8.41 and a beta of 4.52. The stock’s fifty day moving average price is $98.21 and its 200-day moving average price is $70.10.

GRAIL (NASDAQ:GRAL) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($2.46) EPS for the quarter, topping analysts’ consensus estimates of ($3.40) by $0.94. GRAIL had a negative return on equity of 15.69% and a negative net margin of 286.43%.The business had revenue of $36.19 million during the quarter, compared to analysts’ expectations of $33.83 million. As a group, analysts expect that GRAIL, Inc. will post -15.15 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on GRAL shares. Weiss Ratings reissued a “sell (d-)” rating on shares of GRAIL in a report on Thursday, January 22nd. Morgan Stanley raised their target price on GRAIL from $85.00 to $110.00 and gave the company an “equal weight” rating in a report on Monday, December 1st. Canaccord Genuity Group raised their price objective on shares of GRAIL from $85.00 to $105.00 and gave the stock a “buy” rating in a report on Monday, November 17th. Finally, Guggenheim increased their price objective on GRAIL from $100.00 to $130.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $105.00.

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.